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Rare diseases are defined as the diseases 
that affect less than one person in 2,000 people. 
There are about 6000 such disorders, including 
diseases, anomalies and syndromes. About 80% 
of them have genetic origin. However, the num-
ber of patients with a  single disease is small, 
particularly in one country, but if we take into 
account the entire world and the number of 
disorders and patients, there are millions cases 
worldwide.
Many of rare diseases are orphan diseases, 
which are defined as those of limited interest to 
scientists, doctors, healthcare and pharmaceuti-
cal companies. Some of orphan diseases are very 
rare but others are common as so-called neglec-
ted infectious diseases, which are endemic to 
areas ravaged by poverty in Africa, Asia and the 
Americas (tropical infections and infestations: 
lymphatic filariasis, leishmaniasis, African try-
panosomiasis, schistosomiasis, trachoma, oncho-
cerciasis, Chagas disease, etc.).
The epidemiological data on that field are 
spare and with high probability of not being re-
gistered. Frequently, the clinical and radiological 
picture of these diseases vary widely, and in spite 
of patients with spectacular symptoms, there are 
some cases with not pronounced symptoms or 
even occult. It often influences underdiagnoses 
and delayed correct diagnosis. 
In addition, only for few diseases diagnostic 
and therapeutic recommendations have been esta-
blished and many statements still require proving 
in prospective randomized studies.
Rare lung diseases may involve only the 
lung, or the lung can be one of multiple involved 
organs. Usually patients with rare disease require 
multidisciplinary care in highly specialized cen-
ters, however, with tight cooperation with family 
doctors. 
It is underlined that special systems of edu-
cation focused on rare diseases should be em-
ployed for medical students and young doctors 
thus improving awareness of these diseases. All 
respiratory physicians should have some clinical 
and scientific knowledge of the field and should 
be open-minded about diagnosis.
Usually rare diseases are present throughout 
the person’s entire life and apart from medical 
problems, there are many social and psychosocial 
problems that should be resolved. The role of 
patients’ organizations in the field of stimulation 
of health care systems for the improvement of 
health care, social welfare, scientific research, 
implementations of new drugs is outstanding. 
Recently The European Union Committee 
of Experts on Rare Diseases (EUCERD) has es-
tablished recommendations for the criteria of 
centers of expertise for rare diseases in member 
states, their mission and scope, and the criteria 
of their designation. Emphasis has been placed 
upon the development of European reference 
networks, as well as registries and databases, and 
the necessity of a multidisciplinary approach.
The Orphanet website (www.orpha.net) is 
the principle source of important and validated 
information about the rare disorders, for both 
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Table 1. Rare pulmonary diseases
Autoimmune diseases
Anti-basement membrane syndrome
Pulmonary alveolar proteinosis
Amyloidosis
Common variable immunodeficiency disease
Vasculitides
Granulomatosis with polyangitis (Wegener’s disease)
Microscopic polyangitis
Eosinophilic granulomatosis with polyangitis  
(Churg-Strauss syndrome)
Behçet’s disease
Takayasu’s arteritis
Disorders of genetic origin
Lymphangioleiomyomatosis sporadic and associated  
with tuberous sclerosis
Birt-Hogg-Dubé syndrome
Primary ciliary dyskinesia
Alpha-1-antytripsin deficiency
Elhers-Danlos syndrome
Neurofibromatosis
Gaucher disease
Other idiopathic disorders (limited to the lungs)
Idiopathic pulmonary fibrosis
Idiopathic eosinophilic pneumonias
Tracheobronchopathia osteochondroplastica
Tracheobronchomegaly (Mounier-Kuhn syndrome)
Idiopathic bronchiolitis
Other rare diseases 
Thoracic endometriosis
Langerhans’ cell histiocytosis
provide useful information regarding histiocytic 
disorders and LAM. 
Improved clinical and basic scientific know-
ledge, as well as research on rare pulmonary di-
seases should be one of the most important goals 
for all respiratory physicians at the present time 
and in the future.
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patients and doctors. The Polish version of this 
page is full of many recent and important infor-
mation. Also EuroHistionet (www.eurohistio.
net/index_eng) and Histiocytosis Society (www.
histiocytesociety.org), 
American LAM Foundation (www.thelam-
foundation.org) and national LAM web pages 
